Clinical trials · New York
Non Small Cell Lung Cancer clinical trials in New York
We’re tracking 228 recruiting non small cell lung cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06626243Recruiting
Comparing surgery types for lung cancer after pre-surgery therapy
This trial compares different surgical methods (robotic, VATS, or open surgery) used to remove lung cancer after patients have had chemotherapy and/or immunotherapy before their operation. It looks at results from five specialized hospitals to help understand which approach may work best.
New York, New YorkAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
New York, New YorkAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
New York, New YorkAges 18 years+ - NCT05424029Recruiting
Test blood and lung fluid markers to predict lung cancer return
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
Uniondale, New YorkAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
New York, New YorkAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
New York, New YorkAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Brooklyn, New YorkAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Buffalo, New YorkAges 18 years+ - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT06769126RecruitingPhase 2
Personalized treatment study for extensive stage small cell lung cancer
This study uses biomarker tests on your tumor to find a personalized treatment after initial chemotherapy. You will be assigned to one of four treatment groups based on your biomarker results.
Webster, New YorkAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Buffalo, New YorkAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
New York, New YorkAges 18 years+ - NCT06841055RecruitingPhase 2
Pumitamig plus chemo for Stage IV lung cancer after immunotherapy
This trial tests a new investigational drug called Pumitamig (BNT327) given with chemotherapy for people with advanced non-small cell lung cancer (Stage IV) that has continued to grow after one prior treatment with immunotherapy and platinum chemotherapy. The study aims to see if this combination is safe and can help shrink the cancer.
New York, New YorkAges 18 years+ - NCT06855771RecruitingPhase 2
Study of an oral drug for MTAP-deleted advanced lung cancer
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
Shirley, New YorkAges 18 years+ - NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
New York, New YorkAges 18 years+ - NCT06863233RecruitingPhase 1
Immune cell imaging study for people with lung cancer
This study uses an imaging method to look at certain immune cells (CD8+ T cells) in people with advanced non-small cell lung cancer who are about to receive a new cell therapy. It helps researchers understand how the immune system responds during treatment.
Commack, New YorkAges 18 years+ - NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+ - NCT06905197RecruitingPhase 1
Study of DZD6008 for advanced NSCLC with EGFR mutations
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
New York, New YorkAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
New York, New YorkAges 18 years+ - NCT07005128RecruitingPhase 3
New Drug Combo for First-Line Extensive Small Cell Lung Cancer
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
Albany, New YorkAges 18–99 - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT07027514RecruitingPhase 1
Study of Tolododekin Alfa with immunotherapy for advanced lung cancer
This trial tests a new drug, Tolododekin Alfa, combined with an immunotherapy drug for advanced non-small cell lung cancer. It aims to see if this combination can help shrink tumors and improve outcomes.
New York, New YorkAges 18 years+
Non Small Cell Lung Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting non small cell lung cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- NYU Langone Health · 7 studies
- Columbia University Irving Medical Center · 3 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 2 studies
- Memorial Sloan Kettering Commack · 2 studies
- Memorial Sloan Kettering Nassau · 2 studies
- Montefiore Medical Center · 2 studies
What taking part in a non small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Non Small Cell Lung Cancer trials in other states
Common questions
- Are there non small cell lung cancer clinical trials in New York?
- Yes. We're currently tracking 228 recruiting non small cell lung cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non small cell lung cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non small cell lung cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.